Healthcare Sector Review: Watson Files for FDA Approval, Biosimilar Drug Guidelines

Read Trending Stories

Today's Trending Stocks

Click a Company to Research Now:

Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Amgen, Inc. (NASDAQ:AMGN): The FDA released guidelines for the first shortcut to the U.S. market for “biosimilar” drugs, less expensive versions of expensive and complex medicines made from biological matter.

JNJ shares closed at $64.60, down $0.29, or 0.45%, on the day. Its market capitalization is $176.41 billion.

PFE shares closed at $21.05, down $0.09, or 0.43%, on the day. Its market capitalization is $161.81 billion.

AMGN shares closed at $67.36, up $0.52, or 0.78%, on the day. Its market capitalization is $53.62 billion.

Merck & Co., Inc. (NYSE:MRK): Watson Pharmaceuticals (NYSE:WPI) confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application with the U.S. Food and Drug FDA seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg. Watson’s ANDA product is a generic version of Bayer HealthCare Pharmaceuticals’ (BAYRY) Beyaz. Beyaz is an oral contraceptive indicated for use by women to prevent pregnancy, treat symptoms of premenstrual dysphoric disorder for women who choose to use an oral contraceptive for contraception, treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control, and raise folate levels in women who choose to use an oral contraceptive for contraception.

The shares closed at $37.91, down $0.24, or 0.63%, on the day. Its market capitalization is $115.55 billion.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!

Do You Want More Profits? Wall St. Cheat Sheet Premium newsletter subscribers have been crushing the markets with winning stock picks.

Click here now for your FREE trial to our acclaimed flagship newsletter:

Learn More

Advertisement:
Improve your Investing Portfolio with Wall St Cheat Sheet Premium

Intelligent Investing

Wall St. Cheat Sheet Premium

Tired of wasting time and money sifting through the noise on TV, websites, and Twitter? Get winning stock picks now.

Gold & Silver Premium

Join Chicago Mercantile Exchange commentator Eric McWhinnie as he covers Gold & Silver for you.

Commodities Premium

Commodities are heating up. This is an investment newsletter you'll need to win in the bull market.

Wall St. Cheat Sheet has been featured in these fine media outlets: